BioNTech
phase a anti tumor activity dose disease control achieved in of patients four patients with | BioNTech
Company
Deck Type
Sector
Industry
Deck date
November 2020
Slide
19 of 25
Related slides by other companies
AstraZeneca
Investor Day
June 2021
advancing the portfolio key data at and | AstraZeneca
Oculis
Investor Conference
June 2023
is a large and growing market with critical unmet needs | Oculis
Neumora Therapeutics
IPO
September 2023
phase efficacy population patient demographics and characteristics similar across treatment groups | Neumora Therapeutics
Genelux
Investor Presentation
February 2024
primed anti tumor activity primed | Genelux
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights